On November 12. 2021 Thyas reported that it has raised JPY 300 million in Series A3 financing with participation from Kyoto University Innovation Capital Co., Ltd., and D3 LLC (Press release, Thyas , NOV 12, 2021, View Source [SID1234629207]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The funds will be used for accelerating the research and development including preclinical studies of iPS cell-derived immune cell therapy and discovery research of new pipelines for the treatment of solid cancers and infectious diseases. In addition to R&D, Thyas further strives for business development and aims to deliver the early clinical applications to patients as soon as possible.